Try

Surmodics, Inc.

SRDXUnited States

41 filed reports · 519 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$126MFY2024 · to Sep 30, 2024−4.9% from $133M10-K$29.6MQ3 FY2025 · to Jun 30, 2025−2.6% from $30.3M10-Q
Net income-$11.5MFY2024 · to Sep 30, 2024a year earlier: -$1.54M10-K-$5.32MQ3 FY2025 · to Jun 30, 2025a year earlier: -$7.55M10-Q
Operating income-$5.65MFY2024 · to Sep 30, 2024a year earlier: $5.15M10-K-$5.24MQ3 FY2025 · to Jun 30, 2025a year earlier: -$5.37M10-Q

Filed reports

41 reports · Jun 2015 to Jun 2025

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR315,224Jun 2015 to Jun 2025
Annual · 10-KSEC EDGAR104,579Sep 2015 to Sep 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY2025 Q310-QJun 30, 2025Aug 8, 2025368Open
FY2025 Q210-QMar 31, 2025Apr 30, 2025227Open
FY2025 Q110-QDec 31, 2024Jan 30, 2025220Open
FY202410-KSep 30, 2024Nov 20, 2024827Open
FY2024 Q310-QJun 30, 2024Jul 31, 2024163Open
FY2024 Q210-QMar 31, 2024May 1, 2024155Open
FY2024 Q110-QDec 31, 2023Feb 1, 2024155Open
FY202310-KSep 30, 2023Nov 22, 2023395Open
FY2023 Q310-QJun 30, 2023Aug 2, 2023159Open
FY2023 Q210-QMar 31, 2023Apr 26, 2023155Open
FY2023 Q110-QDec 31, 2022Feb 6, 2023154Open
FY202210-KSep 30, 2022Nov 23, 2022412Open

Financial data

519 concepts · 9,803 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial505 concepts · 9,017 facts · Sep 2012 to Jun 2025

  • Cash and cash equivalents at carrying value61 · Sep 2012 to Jun 2025
  • Net income loss59 · Sep 2013 to Jun 2025
  • Operating income loss59 · Sep 2013 to Jun 2025
  • Revenue59 · Sep 2013 to Jun 2025
  • Stockholders equity (US GAAP)58 · Sep 2012 to Jun 2025
  • Allocated share based compensation expense57 · Sep 2013 to Jun 2025
  • Amortization of intangible assets57 · Sep 2013 to Jun 2025
  • Comprehensive income net of tax57 · Sep 2013 to Jun 2025
  • Costs and expenses57 · Sep 2013 to Jun 2025
  • Depreciation depletion and amortization57 · Sep 2013 to Jun 2025
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest57 · Sep 2013 to Jun 2025
  • Income tax expense benefit57 · Sep 2013 to Jun 2025
  • Investment income net57 · Sep 2013 to Jun 2025
  • Nonoperating income expense57 · Sep 2013 to Jun 2025
  • Other comprehensive income loss net of tax57 · Sep 2013 to Jun 2025
  • Selling general and administrative expense57 · Sep 2013 to Jun 2025
  • Deferred income tax expense benefit56 · Sep 2013 to Jun 2025
  • Increase decrease in accrued income taxes payable56 · Sep 2013 to Jun 2025
  • Increase decrease in inventories56 · Sep 2013 to Jun 2025
  • Payments to acquire property plant and equipment56 · Sep 2013 to Jun 2025
  • Proceeds from issuance of common stock56 · Sep 2013 to Jun 2025
  • Earnings per share basic55 · Sep 2013 to Jun 2025
  • Earnings per share diluted55 · Sep 2013 to Jun 2025
  • Unrecognized tax benefits that would impact effective tax rate55 · Sep 2013 to Jun 2025

Segment11 concepts · 659 facts · Sep 2013 to Jun 2025

  • Revenue360 · Sep 2013 to Jun 2025
  • Depreciation depletion and amortization114 · Sep 2013 to Jun 2025
  • Operating income loss114 · Sep 2013 to Jun 2025
  • Goodwill foreign currency translation gain loss42 · Sep 2016 to Jun 2025
  • Goodwill acquired during period9 · Dec 2015 to Sep 2021
  • Goodwill translation adjustments9 · Dec 2015 to Dec 2016
  • Research Development And Other Revenue4 · Dec 2017 to Mar 2019
  • Goodwill impairment loss3 · Sep 2013 to Sep 2015
  • Goodwill purchase accounting adjustments2 · Sep 2022
  • Income tax reconciliation change in deferred tax assets valuation allowance1 · Sep 2016
  • Realized investment gains losses1 · Sep 2016

Product3 concepts · 127 facts · Sep 2016 to Jun 2025

  • Revenue120 · Sep 2016 to Jun 2025
  • Annual Minimum Payments For License4 · Sep 2019 to Dec 2019
  • Cost of goods and services sold (US GAAP)3 · Sep 2018

Segments

786 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments2 members · 641 facts

  • Medical Device [Member]375 · Sep 2013 to Jun 2025
  • In Vitro Diagnostics [Member]266 · Sep 2013 to Jun 2025

Product or service4 members · 127 facts

  • Royalties and License Fees [Member]42 · Sep 2016 to Jun 2025
  • Product sales [Member]41 · Sep 2016 to Jun 2025
  • Research, Development and Other [Member]37 · Sep 2017 to Jun 2025
  • License [Member]7 · Sep 2018 to Dec 2019

Subsegments2 members · 18 facts

  • Performance Coatings [Member]15 · Sep 2021 to Jun 2025
  • SurVeil DCB - Abbott Agreement [Member]3 · Sep 2021 to Sep 2023

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Surmodics, Inc. (SRDX) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.